Ocular Therapeutix To Present Late-Breaking Abstract Of HELIOS Study At 42nd ASRS Annual Scientific Meeting

7/10/24 8:11:27 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OCUL alert in real time by email

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that a late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal implant) for non-proliferative diabetic retinopathy (NPDR) was accepted for presentation at the 42nd American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held July 17-20 in Stockholm, Sweden.

Get the next $OCUL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OCUL

Date	Price Target	Rating	Analyst
10/16/2024		Sector Outperform	Scotiabank
6/20/2024	$7.00 → $11.00	Hold → Buy	TD Cowen
5/31/2024	$15.00	Overweight	Piper Sandler
2/9/2024	$15.00	Buy	BofA Securities
4/21/2023	$18.00	Outperform	Robert W. Baird
8/10/2022	$15.00	Buy	Berenberg
3/1/2022	$30.00 → $22.00	Market Outperform	JMP Securities
11/9/2021	$27.00 → $30.00	Market Outperform	JMP Securities

More analyst ratings

$OCUL
Financials

Live finance-specific insights

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the
11/14/24 7:00:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. Conference Call and Webcast Information: Date: Thursday, November 14, 2024, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201)
11/6/24 7:30:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Ocular Therapeutix™ Reports Second Quarter 2024 Results
SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the se
8/7/24 7:10:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care

$OCUL
Leadership Updates

Live Leadership Updates

Ocular Therapeutix® to Host Investor Day on June 13, 2024
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD
6/5/24 7:30:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Ocular Therapeutix™ Reports First Quarter 2024 Results
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati
5/7/24 4:05:00 PM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc
4/16/24 7:00:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care

$OCUL
Press Releases

Fastest customizable press release news feed in the world

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the
11/14/24 7:00:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV. Jefferies London Healthcare Conference 2024Fireside Chat Date: Wednesday, November 20, 2024 Fireside Chat Time: 9:00 AM GMT Location: London, UK A live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of the Company's web
11/13/24 7:30:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
BEDFORD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that Namrata Saroj, OD, has joined the Company on a full-time basis as Chief Business Officer (CBO). Dr. Saroj previously served as Development Strategy Consultant to Ocular since February 2024. "I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief Business Officer. She brings a unique perspective to the
11/12/24 7:30:00 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care

Ocular Therapeutix To Present Late-Breaking Abstract Of HELIOS Study At 42nd ASRS Annual Scientific Meeting
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that a late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal implant) for non-proliferative diabetic retinopathy (NPDR) was accepted for presentation at the 42nd American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held July 17-20 in Stockholm, Sweden.
7/10/24 8:11:27 AM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler Maintains Overweight on Ocular Therapeutix, Maintains $15 Price Target
Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price target.
6/21/24 1:42:42 PM ET
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA
6/20/24 1:26:29 PM ET
$ALUR
$AMD
$APLD
$ASNS
Medical/Dental Instruments
Health Care
Semiconductors
Technology

Ocular Therapeutix To Present Late-Breaking Abstract Of HELIOS Study At 42nd ASRS Annual Scientific Meeting

Chat with this insight

Recent Analyst Ratings for $OCUL

$OCUL Financials

Live finance-specific insights

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Reports Second Quarter 2024 Results

$OCUL Leadership Updates

Live Leadership Updates

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

$OCUL Press Releases

Fastest customizable press release news feed in the world

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

$OCUL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Legal Officer Anderman Todd was granted 98,700 shares (SEC Form 4)

SEC Form 3 filed by new insider Anderman Todd

Chief Development Officer Kaiser Peter was granted 100,000 shares, increasing direct ownership by 86% to 215,984 units (SEC Form 4)

$OCUL Market Insights

Live Market Insights

$OCUL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$OCUL Large Ownership Changes

This live feed shows all institutional transactions in real time.

$OCUL SEC Filings

$OCUL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.